Norway's ArcticZymes Q4 revenue up on GMP-grade product sales

Arcticzymes Technologies ASA

12/02/2026 06:09

Overview

Norwegian enzyme maker's Q4 revenue grew 31% yr/yr

Q4 EBITDA increased significantly, reflecting improved operating leverage

Company maintains strong balance sheet with no interest-bearing debt

Outlook

ArcticZymes focuses on scaling Biomanufacturing with increased GMP-grade penetration

Company plans expansion of CDMO partnerships for long-term revenue visibility

ArcticZymes aims to expand RNA enzyme portfolio, including launch of ET-N1

Result Drivers

BIOMANUFACTURING GROWTH - Biomanufacturing revenue rose 25% YoY, driven by increased GMP-grade product sales and adoption among CDMO customers

MOLECULAR TOOLS PERFORMANCE - Molecular Tools revenue increased 55% YoY in Q4, aided by key account activity and broader customer growth

STRONG FINANCIAL POSITION - ArcticZymes maintains a strong balance sheet with no interest-bearing debt, supporting expansion and strategic investments

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
NOK 34.70 mln
Q4 EBITDA
NOK 8.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Arcticzymes Technologies ASA is NOK32.00, about 48.8% above its February 11 closing price of NOK21.50

The stock recently traded at 52 times the next 12-month earnings vs. a P/E of 74 three months ago

Press Release: ID:nWkrb1NwKW

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)